Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 166, Issue 1, 2014, Pages 76-84

  Shuldiner, Alan R ^a,b   Palmer, Kathleen ^a   Pakyz, Ruth E ^a   Alestock, Tameka D ^c   Maloney, Kristin A ^a   O'Neill, Courtney ^d   Bhatty, Shaun ^e   Schub, Jamie ^f   Overby, Casey Lynnette ^a   Horenstein, Richard B ^a   Pollin, Toni I ^a   Kelemen, Mark D ^c   Beitelshees, Amber L ^a   Robinson, Shawn W ^b   Blitzer, Miriam G ^a,f   Mcardle, Patrick F ^a   Brown, Lawrence ^a,b   Jeng, Linda Jo Bone ^a,g   Zhao, Richard Y ^a   Ambulos, Nicholas ^f   Vesely, Mark R ^a   more..

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Division of Cardiovascular Medicine   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^f University of Maryland Medical Center ^*

^g Translational Genomics Laboratory   (United States)

Author keywords

Anti platelet pharmacogenetics; Clopidogrel; CYP2C19; Implementation science; Individualized medicine; Personalized medicine; Pharmacogenomics; Translational research

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ARTICLE; CYP2C19 GENE; GENE; GENETIC SCREENING; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEART CATHETERIZATION; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; UNIVERSITY HOSPITAL;

ANTI-PLATELET PHARMACOGENETICS; CLOPIDOGREL; CYP2C19; IMPLEMENTATION SCIENCE; INDIVIDUALIZED MEDICINE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; TRANSLATIONAL RESEARCH;

ACADEMIC MEDICAL CENTERS; ARYL HYDROCARBON HYDROXYLASES; CARDIAC CATHETERIZATION; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MARYLAND; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PROGRAM DEVELOPMENT;

EID: 84896319906     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.31396     Document Type: Article

References (31)

1. Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. 2014. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 21:e93-e99.
2. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS II, Lachno DR, Salazar D, Winters KJ. 2007. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429-2436.
3. Chevalier BR. 2013. GIANT: A prospective registry study of CYP2C19 genetic profiling for thienopyridine management after primary PCI in acute myocardial infarction. San Francisco, CA: Transcatheter Cardiovascular Therapeutics.
4. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC. 2012. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321-326.
5. Depta JP, Bhatt DL. 2012. Antiplatelet therapy and proton pump inhibition: Cause for concern? Curr Opin Cardiol 27:642-650.
6. Farrugia G, Weinshilboum RM. 2013. Challenges in implementing genomic medicine: The Mayo Clinic Center for Individualized Medicine. Clin Pharmacol Ther 94:204-206.
7. Fisch AS, Perry CG, Stephens SH, Horenstein RB, Shuldiner AR. 2013. Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep 15:381.
8. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. 2003. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908-2913.
9. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. 2006. Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247.
10. Johnson JA, Elsey AR, Clare-Salzler MJ, Nessl D, Conlon M, Nelson DR. 2013. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: Clinical implementation of pharmacogenetics. Pharmacogenomics 14:723-726.
11. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB. 2011. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90:625-629.
12. Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR. 2012. Clopidogrel: A case for indication-specific pharmacogenetics. Clin Pharmacol Ther 91:774-776.
13. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124:2574-2609.
14. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, Frazer KA, Korf B, Ledbetter DH, Lupski JR, Marsh C, Mrazek D, Murray MF, O'Donnell PH, Rader DJ, Relling MV, Shuldiner AR, Valle D, Weinshilboum R, Green ED, Ginsburg GS. 2013. Implementing genomic medicine in the clinic: The future is here. Genet Med 15:258-267.
15. McCarthy JJ, McLeod HL, Ginsburg GS. 2013. Genomic medicine: A decade of successes, challenges, and opportunities. Sci Transl Med 5:189sr184.
16. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. 2010a. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a meta-analysis. JAMA 304:1821-1830.
17. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. 2010b. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 304:1821-1830.
18. Perry CG, Shuldiner AR. 2013. Pharmacogenomics of anti-platelet therapy: How much evidence is enough for clinical implementation? J Hum Genet 58:339-345.
19. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. 2008. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322:1702-1705.
20. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks HH, Wilke RA, Clayton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, Roden DM. 2012. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 92:87-95.
21. Rampersaud E, Damcott CM, Fu M, Shen H, McArdle P, Shi X, Shelton J, Yin J, Chang YP, Ott SH, Zhang L, Zhao Y, Mitchell BD, O'Connell J, Shuldiner AR. 2007. Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: Evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 56:3053-3062.
22. Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E., 2012. Cost-effectiveness of cytochrome P450 2C19 Genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 32:323-332.
23. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE. 2013. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 93:324-325.
24. Relling MV, Klein TE. 2011. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89:464-467.
25. Scott SA, Owusu Obeng A, Hulot JS. 2013a. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol 10:175-189.
26. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR. 2013b. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94:317-323.
27. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. 2009. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857.
28. Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE, Vesely M, Robinson SW, Ambulos N Jr, Stass SA, Kelemen MD, Brown LA, Pollin TI, Beitelshees AL, Zhao RY, Pakyz RE, Palmer K, Alestock T, O'Neill C, Maloney K, Branham A, Sewell D, Crews K, Hoffman J, Cross S, Haidar C, Baker D, Bell G, Greeson F, Gaur A, Reiss U, Huettel A, Cheng C, Gajjar A, Pappo A, Howard S, Hudson M, Pui CH, Jeha S, Evans WE, Broeckel U, Altman RB, Gong L, Whirl-Carrillo M, Manickam K, Sweet KM, Embi PJ, Roden D, Peterson J, Denny J, Schildcrout J, Bowton E, Pulley J, Beller M, Mitchell J, Danciu I, Price L, Weinshilboum R, Wang L, Nelson D, Clare-Salzler M, Elsey A, Burkley B, Langaee T, Liu F, Nessl D, Dong HJ, Lesko L, Chute CG. 2013. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming challenges of real-world implementation. Clin Pharmacol Ther 94:207-210.
29. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. 2009. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375.
30. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M. 2012. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 92:112-117.
31. Xie X, Ma YT, Yang YN, Li XM, Zheng YY, Ma X, Fu ZY, Ba B, Li Y, Yu ZX, Chen Y, Chen BD, Liu F, Huang Y, Liu C, Baituola G. 2013. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial. Int J Cardiol 168:3736-3740.